← Back to Search

Other

TTHX1114(NM141) for Corneal Endothelial Dystrophy

Phase 2
Waitlist Available
Research Sponsored by Trefoil Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28
Awards & highlights
No Placebo-Only Group

Summary

This trial involves a known treatment given to all participants.

Eligible Conditions
  • Corneal Endothelial Dystrophy
  • Fuchs' Dystrophy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Best Corrected Visual Acuity

Side effects data

From 2021 Phase 1 & 2 trial • 22 Patients • NCT04520321
14%
Eye irritation
14%
Photophobia
14%
Iritis
14%
Punctate keratitis
14%
Eye pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vehicle (Placebo)
High-dose
Low Dose
Mid-dose

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: Group 3aExperimental Treatment1 Intervention
Study subjects in Group 3a will consist of subjects who had participated in in Group 3 if not recovered from DWEK/ DSO by the median time observed in Group 2 and will receive TTHX1114 (4 injections)
Group II: Group 3 TTHX1114 in combination with DWEK/DSOExperimental Treatment1 Intervention
Study subjects in Group 3 will receive TTHX1114 (1 injection) and undergo DWEK/ DSO
Group III: Group 2 TTHX1114 in combination with DWEK/DSOExperimental Treatment1 Intervention
Study subjects in Group 2 will receive TTHX1114 (5 injections) and undergo DWEK/ DSO
Group IV: Group 1aExperimental Treatment1 Intervention
Study subjects in Group 1a will consist of subjects in Group 1 if not recovered from DWEK/ DSO by Day 84 and will receive TTHX1114 (5 injections)
Group V: Group 1 DWEK/DSOActive Control1 Intervention
Study subjects in Group 1 will undergo DWEK/ DSO and will not receive any TTHX1114
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TTHX1114(NM141)
2021
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

Trefoil Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
71 Total Patients Enrolled
Thomas TremblayStudy DirectorTrefoil Therapeutics.com
2 Previous Clinical Trials
49 Total Patients Enrolled
~10 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top